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Abstract
Background: Although chemopreventative agents targeting the estrogen/estrogen receptor (ER) pathway have
been effective for ER+ breast cancers, prevention of hormone receptor-negative breast cancers, such as Her2/erbB-2
+ breast cancers, remains a significant issue. Previous studies have demonstrated that administration of EGFR/
erbB-2-targeting lapatinib to MMTV-erbB-2 transgenic mice inhibited mammary tumor development. The
prevention, however, was achieved by prolonged high dose exposure. The tolerance to high dose/long-term
drug administration may hinder its potential in clinical settings. Therefore, we aimed to test a novel, short-term
chemopreventative strategy using lapatinib during the premalignant risk window in MMTV-erbB-2 mice.
Methods: We initially treated cultured cells with lapatinib to explore the anti-proliferative effects of lapatinib
in vitro. We used a syngeneic tumor graft model to begin exploring the in vivo anti-tumorigenic effects of lapatinib in
MMTV-erbB-2 mice. Then, we tested the efficacy of brief exposure to lapatinib (100 mg/kg/day for 8 weeks),
beginning at 16 weeks of age, in the prevention of mammary tumor development in MMTV-erbB-2 mice.
Results: In the syngeneic tumor transplant model, we determined that lapatinib significantly inhibited tumor cell
proliferation. Furthermore, we demonstrated that short-term lapatinib exposure resulted in life-long protective
effects, as supported by increased tumor latency in lapatinib-treated mice compared to the control mice. We
further established that delayed tumor development in the treated mice was preceded by decreased BrdU nuclear
incorporation and inhibited mammary morphogenesis. Molecular analysis indicated that lapatinib inhibited
phosphorylation and expression of EGFR, erbB-3, erbB-2, Akt1, and Erk1/2 in premalignant mammary tissues. Also,
lapatinib drastically inhibited the phosphorylation and expression of ERα and the transcription of ER target genes in
premalignant mammary tissues. We also determined that lapatinib suppressed the stemness of breast cancer cell
lines, as evidenced by decreased tumorsphere formation and ALDH+ cell populations.
Conclusions: Taken together, these data demonstrate that brief treatment with EGFR/erbB-2-targeting agents before
the onset of tumors may provide lifelong protection from mammary tumors, through the concurrent inhibition of
erbB-2 and ER signaling pathways and consequential reprogramming. Our findings support further clinical testing to
explore the benefit of shorter lapatinib exposure in the prevention of erbB-2-mediated carcinogenesis.
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Background
Although early diagnosis and various therapies for breast
cancer patients have improved clinical outcomes, redu-
cing the prevalence of breast cancer risk and eradicating
this morbid disease remains a significant challenge.
Therefore, development of novel preventive agents and
strategies is of pivotal importance in this regard. For
breast cancer prevention, use of endocrine modulators
that target estrogen signaling or production, such as
tamoxifen or letrozole, has proven to be a successful
strategy to prevent and treat estrogen receptor-positive
(ER+) breast cancers [1–3]. However, effective manage-
ment of ER-negative (ER-) breast cancers remains under
development.
erbB-2/Her2+ breast cancers account for approxi-
mately 30% of breast cancer cases [4]. Likewise, erbB-2
amplification has been associated with poor prognosis,
metastasis, and therapeutic resistance [5, 6]. erbB-2 is a
member of the epidermal growth factor receptor (EGFR)
family, which also includes EGFR, erbB-3, and erbB-4.
This family of receptor tyrosine kinases (RTKs) plays a
critical role in cell proliferation, survival, migration, and
angiogenesis [7–9]. Of note, erbB-2 is an ‘orphan
receptor’ and its activation mainly relies on its inter-
action with other EGFR family members [10–12]. A
number of novel therapeutics targeting erbB-2 and its
family members have been developed and used clinically,
which has significantly improved patient outcomes [13,
14]. Of these novel agents, lapatinib, an oral RTK inhibi-
tor, has been approved by the US Food and Drug
Administration for use on erbB-2+, locally advanced or
metastatic breast cancers [15]. Lapatinib reversibly binds
to the kinase domains of erbB-2 and EGFR to block
receptor phosphorylation and activation, which results
in the inhibition of downstream signaling pathways, in-
cluding the mitogen-activated protein kinase (MAPK)/
Erk and phosphatidylinositol 3-kinase (PI3K)/Akt path-
ways [16–18]. Selective inhibition of erbB-2/EGFR-medi-
ated signaling presents lapatinib as a promising drug to
target erbB-2/EGFR-overexpressing breast cancers.
While the development of erbB-2-targeted therapeutics
continues, preventative strategies targeting erbB-2/EGFR
are emerging. It has been demonstrated that lapatinib pre-
vents mammary tumor development in mouse mammary
tumor virus (MMTV)-erbB-2 transgenic mice; however,
the chemopreventive effect in the study was based on
long-term, high dose exposure to lapatinib (12 months,
75 mg/kg twice daily) [19]. Although this drug is regarded
as well-tolerated, life-long treatment may compromise the
application of lapatinib as a chemopreventive agent. In
order to further unveil the possibility of lapatinib therapy
in breast cancer chemoprevention, we investigated the ef-
fect of short-term lapatinib exposure during the
premalignant risk window on the development of
mammary tumors in MMTV-erbB-2 transgenic mice.
MMTV-erbB-2 transgenic mice are a clinically relevant
model of erbB-2-overexpressing breast cancers with a
defined genetic background and tumors forming at
approximately 35 weeks of age. Our strategy aimed to use
lapatinib to prevent erbB-2-mediated carcinogenesis with
a short-term, low dose (8 weeks, 100 mg/kg once daily)
approach to demonstrate a lesser risk of toxicity, better
medication adherence, and, thereby, an acceptable risk-
benefit ratio. All of these factors are critical to the success
of a cancer risk reduction intervention in clinical practice.
Indeed, we found that this strategy can delay the develop-




Lapatinib was purchased from LC Laboratories (Woburn,
MA). The following antibodies were purchased from Cell
Signaling (Danvers, MA): EGFR, phospho-EGFR
(Ser1046/1047), phospho-erbB-2 (Tyr877), phospho-erbB-
3 (Tyr1289), phospho-Akt (Ser473), and phospho-ERα
(Ser167); Millipore (Temecula, CA): ERα and erbB-2; and
Santa Cruz Biotechnology (Santa Cruz, CA): erbB-3, c-
Myc, Erk2, phospho-Erk, Bcl-2, cyclin D1, and β-actin.
Horseradish peroxidase (HRP)-labeled goat anti-rabbit
and anti-mouse secondary antibodies were used from
Thermo Scientific (Rockford, IL).
Cell culture
The erbB-2-overexpressing mammary tumor cell lines,
78617 and 85815, used in this study were established
from mammary tumors of FVB/N-Tg/MMTV-erbB-2
mice as previously described [20]. BT474 and SKBR3
cells were purchased from the American Type Culture
Collection (ATCC; Manassas, VA). All cells were main-
tained in DMEM/F-12 culture medium supplemented
with 10% fetal bovine serum (FBS), penicillin (100 μg/
ml), and streptomycin (100 μg/ml) in a humidified incu-
bator with 5% CO2 at 37 °C.
MTS assay
In vitro cell proliferation was determined by an MTS assay
using the CellTiter 96 AQueous One Solution Cell
Proliferation assay kit (Promega; Madison, WI) according
to the manufacturer’s instructions. Briefly, 500 cells per
well were seeded in 96-well plates. After 24 h, cells were
treated with indicated concentrations of lapatinib for
4 days. Then, MTS solution was added to each well and
incubated for 2 h at 37 °C. The survival fraction was deter-
mined based on the absorbance detected at 490 nm using
the SynergyMx microplate reader (BioTek; Winooski,
VT). Each experiment was performed in triplicate.
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Western blotting
Cells or homogenized tissues were incubated in lysis
buffer to extract total protein. The protein was quantified
using a BCA Protein Assay kit (Thermo Scientific Pierce).
Equal sample concentrations (50 μg protein) were loaded
in 10 or 12% SDS-PAGE gels for electrophoresis. After
separation, proteins were transferred to nitrocellulose
membranes and blocked in 5% non-fat dry milk for 1 h.
Primary antibodies were incubated overnight at 4 °C.
Then, membranes were washed and incubated in appro-
priate HRP-labeled secondary antibodies for 1.5 h at room
temperature. Proteins were enhanced using SuperSignal
West Pico Chemiluminescent solution (Thermo Fisher
Scientific) and detected using a FluorChemE imager.
Animals and treatments
Female FVB/N-Tg/MMTV-erbB-2 (MMTV-erbB-2)
transgenic mice were purchased from Jackson Labs (Bar
Harbor, ME). The mice were fed an AIN-93G diet (Har-
lan Teklad; Madison, WI). All animal experiments were
conducted according to IACUC-approved protocols.
For the syngeneic tumor graft model, viable 78617 cells
(1 × 106) were subcutaneously injected into the flanks of
8-week-old mice (n = 5 per group). After 7 days, lapatinib
(100 mg/kg) or vehicle (distilled water containing 1%
Tween 80) were administered daily via oral gavage for
14 days. Tumor volumes were calculated based on the for-
mula: tumor volume = longest diameter × shortest diam-
eter2 × 0.5. By the endpoint, mice were euthanized and
tumors were collected for analysis.
For the preventive experiment using a short-term lapa-
tinib treatment, MMTV-erbB-2 transgenic mice were
administered vehicle or lapatinib (100 mg/kg/day) via
oral gavage 6 days a week from 16 weeks of age to
24 weeks of age (n = 30 per group). After 8 weeks of
treatment (at 24 weeks of age), five mice from each
group were euthanized and mammary glands were
collected for whole mount, immunohistochemistry
(IHC), protein, and RNA analyses. The remaining mice
in each group were monitored for tumor development
by twice-a-week examination beginning at 20 weeks of
age. The latency of tumor development was defined as
the detection of the first palpable tumor. The tumor-free
interval was presented with a Kaplan-Meier survival
curve.
Mammary whole mount preparation
Tissue from the abdominal mammary gland was
mounted onto a glass slide and fixed in Carnoy’s solu-
tion (6:3:1 ratio of 100% ethanol:chloroform:glacial
acetic acid). Following overnight fixation, samples were
rehydrated in serial dilutions of ethanol for 30 min and
were stained overnight in carmine alum stain. Then, the
samples were dehydrated with 70, 95, and 100% ethanol
before being cleared in xylene and mounted with Per-
mount (Thermo Fisher Scientific). The ductal architec-
ture of whole mounts was examined under the Nikon
Eclipse 80i microscope and images were captured using
the Nikon Elements Imaging System (Nikon Instru-
ments, Inc.).
BrdU incorporation assay
Mice were intraperitoneally injected with 200 μl of 5-
bromo-2’-deoxyuridine (BrdU; 3 mg/ml) solution 90 min
before euthanization. The inguinal mammary glands
were collected and fixed with 10% formalin for paraffin
embedding, followed by BrdU detection with IHC.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) assay
Apoptosis was measured in tumor and mammary gland
tissues using an ApopTag Peroxidase In Situ Apoptosis
Detection kit (Millipore) according to the manufacturer’s
instructions. Briefly, formalin-fixed paraffin-embedded
(FFPE) tissue sections (5 μm thick) were deparaffinized
with xylene and rehydrated with ethanol. Then, protein-
ase K (20 μg/ml) was added to the slides at room
temperature for 15 min. After washing in deionized
water, endogenous peroxidase activity was blocked with
3% H2O2 at room temperature for 5 min. Slides were
then washed in PBS and incubated in Equilibration Buf-
fer, followed by 1 h incubation in TdT enzyme at 37 °C.
The reaction was stopped by adding Stop/Wash Buffer
at room temperature for 10 min. Next, anti-
digoxignenin conjugate was added to each slide and the
slides were incubated at room temperature for 30 min.
The slides were washed four times in PBS before the
color was developed using diaminobenzidine (DAB) at
room temperature. The slides were immediately washed
in deionized water to stop the DAB reaction, counter-
stained with hematoxylin, dehydrated with xylene, and
mounted with Permount. Stained sections were analyzed
using the Nikon Eclipse 80i microscope and Nikon Ele-
ments Imaging System Software. The number of tumor
or mammary epithelial cells with TUNEL-specific
staining was recorded to calculate the percentage of
TUNEL-positive cells.
Immunohistochemistry
FFPE mammary gland sections were deparaffinized and
rehydrated as mentioned above in the TUNEL assay
protocol. Antigen retrieval was performed by boiling
tissue sections in citrate buffer (pH 6.0) at 100 °C for
30 min, followed by DNA denaturation with 2 N HCl at
37 °C for 30 min for the BrdU-treated samples. Next,
endogenous peroxidase activity was blocked with 3%
H2O2 in methanol for 10 min at room temperature.
Nonspecific binding was then blocked with 10% horse
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serum prior to overnight incubation at 4 °C with primary
antibodies against BrdU (diluted 1:1000) and ERα
(diluted 1:2000). The sections were incubated with ap-
propriate secondary antibodies for 1 h, followed by
exposure to the ABC reagent (Vector Laboratories; Bur-
lingame, CA) and DAB. Slides were counterstained with
hematoxylin and mounted for observation. Stained sec-
tions were analyzed using the Nikon Eclipse 80i
microscope and Nikon Elements Imaging System Soft-
ware. The number of mammary epithelial or tumor cells
with specific staining of BrdU or ERα was recorded to
calculate the percentage of positive cells.
Real-time PCR
Total RNA was isolated from mammary tissues using a
Qiagen RNeasy Mini kit (Qiagen; Valencia, CA) accord-
ing to the manufacturer’s recommendations. RNA (1 μg)
was reversely transcribed using iScript cDNA Synthesis
Kit (Bio-Rad; Hercules, CA). Real-time PCR (RT-PCR)
was performed using a CFX 96TM Real-Time PCR Sys-
tem (Bio-Rad). The PCR reactions were initiated with
enzyme activation at 95 °C for 30 s, followed by 40 amp-
lification cycles at 95 °C for 5 s and 56–60 °C for 10 s.
Melt curves were completed at 65–95 °C for 10 s per
step. Samples were analyzed in triplicate and β-actin was
used for normalization. The relative mRNA levels of
each gene in the lapatinib-treated samples versus the
control samples were calculated using the comparative
Ct (2ΔΔCt) method.
Tumorsphere assay
BT474 or 78617 cells were seeded (2 × 103 cells/well) in
triplicate in ultra-low attachment 6-well plates
(Corning). Spheres were treated with indicated doses of
lapatinib and incubated in DMEM/F-12 medium supple-
mented with 5 mg/ml insulin (Sigma; St. Louis, MO),
0.5 μg/ml hydrocortisone (Sigma), 1x B-27 (Thermo
Fisher Scientific), 20 ng/ml EGF (Sigma), 20 ng/ml bFGF
(Stemcell Technologies; Cambridge, MA), and 4 μg/ml
heparin (Stemcell Technologies) for 6 days. The number
of primary spheres were counted based on sphere sizes
ranging from 80 to 120 μm in diameter. Then, primary
spheres were trypsinized and vigorously pipetted to form
a single cell suspension. To analyze secondary sphere
formation, these collected cells were resuspended in the
sphere culture medium under the given conditions for
another 6 days. The recorded primary and secondary
tumorsphere numbers were graphed for comparison.
ALDH1 assay
Flow cytometric analysis of aldehyde dehydrogenase 1
(ALDH1) activity was measured using an ALDEFLUOR
Kit (Stemcell Technologies) and Cell Lab Quanta SC
software (Beckman Coulter) according to the
manufacturers’ instructions. Briefly, control or lapatinib-
treated cells were incubated with the ALDEFLUOR sub-
strate for 30 min at 37 °C. The specific inhibitor of
ALDH, diethylaminobenzaldehyde (DEAB), was used to
establish the baseline fluorescence and define the
ALDEFLUOR-positive region. All treatments were per-
formed and analyzed by flow cytometry in triplicate.
Statistical analysis
The tumor latency differences between the groups were
examined using a log rank test based on Kaplan-Meier
survival curves. The significant differences between two
groups in all other experiments were determined by
two-sided Student’s t-tests. P-values of ≤ 0.05 were con-
sidered statistically significant.
Results
Lapatinib suppresses cell proliferation of 78617 and
85815 cells in vitro through inhibition of RTK signaling
As a preliminary experiment for in vivo studies, we
tested the effects of lapatinib on cell proliferation in
erbB-2-overexpressing 78617 and 85815 cells, which
were derived from MMTV-erbB-2 transgenic mouse
mammary tumors [20]. As in Fig. 1a, we showed that
exposure to low dose lapatinib (0.062 – 1 μM) dose-
dependently decreased cell survival in both cell lines.
We further demonstrated that lapatinib-mediated sup-
pression of proliferation in both cell lines was closely
associated with remarkable inhibition of RTK signal-
ing downstream of EGFR and erbB-2. We found that
treatment with lapatinib for 24 h led to a dose-
dependent suppression of EGFR, erbB-2, Akt, and
Erk1/2 activation/phosphorylation in both cell lines
(Fig. 1b-c). Lapatinib also induced a concurrent de-
crease in the expression of Cyclin D1, c-myc, and Bcl-
2, which are critical regulators of cell proliferation and
survival (Fig. 1b-c). These results are corroborated in
other studies using human erbB-2-overexpressing
breast cancer cell lines, including BT474, SKBR3, and
MDA-MB-361 cells [21–24]. In particular, our results
indicate that erbB-2-positive tumor cells derived from
MMTV-erbB-2 transgenic mice were sensitive to lapa-
tinib in vitro and the molecular signaling was specific-
ally inhibited in accordance with erbB-2/EGFR-
targeting therapeutics.
Lapatinib inhibits in vivo tumor growth in the syngeneic
tumor graft model using 78617 cells
To test the in vivo efficacy of lapatinib on tumor cells
derived from MMTV-erbB-2 transgenic mice, we
transplanted syngeneic 78617 cells into the flanks of
female mice, followed by lapatinib (100 mg/kg/day)
treatment for 14 days. As shown in Fig. 2a-b, lapatinib
significantly inhibited tumor growth after 2 weeks of
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treatment. Multiple reports have also demonstrated
that lapatinib abrogates tumor growth in xenograft
mouse models using the BT474 human breast can-
cer cell line [25–28]. Consistently, when the har-
vested syngeneic tumors were stained for BrdU and
TUNEL expression, we observed evident reduced
cell proliferation and a decrease in apoptosis in the
lapatinib-treated mice as compared to the vehicle-
treated mice (Fig. 2c-d). Once more, these in vivo
data provide further support to the notion that
MMTV-erbB-2 mammary tumors are susceptible to
lapatinib treatment.
Short-term exposure to lapatinib during the risk window
increases mammary tumor latency in MMTV-erbB-2 trans-
genic mice
Based on our in vitro and syngeneic in vivo data, we
tested the preventative efficacy of lapatinib in MMTV-
erbB-2 transgenic mice using a novel strategy. Our goal
was to develop a regimen that can achieve effective
mammary tumor prevention with shorter exposure to
lapatinib during the premalignant risk window. To this
end, 16-week-old MMTV-erbB-2 mice were treated with
lapatinib (100 mg/kg/day) for 8 weeks, which concluded
at 24 weeks of age. This short-term exposure to lapatinib
Fig. 1 Lapatinib suppresses cell proliferation of 78617 and 85815 cells in vitro through RTK signaling inhibition. a An MTS assay of cell
proliferation in 78617 and 85815 cells is shown after exposure for 4 days of indicated concentrations of lapatinib. Values are displayed as means
± standard error (S.E.). 78617 (b) and 85815 (c) cells were treated with lapatinib at indicated concentrations for 24 h. Expression and
phosphorylation of specific markers were detected using Western blot analysis
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produced a dramatic delay in the onset of mammary
tumors as compared to the control mice (Fig. 3). Dis-
tinctively, lapatinib-treated mice developed palpable
tumors beginning at 33 weeks of age, while vehicle-
treated mice developed tumors beginning at 25 weeks
of age. This lapatinib-induced increase in tumor
latency was maintained throughout the experiment,
with the average latency for control and lapatinib
groups being 37 and 42 weeks, respectively (p =
0.0154). Our data suggest that short-term, low dose
exposure to lapatinib demonstrates efficacy in breast
cancer prevention in genetically predisposed at-risk
populations.
Short-term exposure to lapatinib impedes mammary
morphogenesis and suppresses cell proliferation
Advanced mammary morphology is associated with
breast cancer susceptibility in humans and is typically
present in premalignant mammary tissues of MMTV-
erbB-2 transgenic mice [29, 30]. To this end, we col-
lected mammary glands of 24-week-old mice to examine
the effects of lapatinib on breast tissue morphogenesis.
As postulated, lapatinib (100 mg/kg/day) treatment for
8 weeks markedly inhibited mammary ductal growth
and branching, as made evident by the decreased com-
plexity of lateral branches and alveolar structures
(Fig. 4a). These alterations demonstrate that lapatinib
Fig. 2 Lapatinib inhibits in vivo growth of syngeneic-grafted tumor cells. Eight-week-old MMTV-erbB-2 transgenic mice were subcutaneously
injected with 1 × 106 78617 cells. The animals were then treated with 100 mg/kg/day lapatinib or vehicle control for 14 days. Tumor growth was
monitored three times a week for three weeks. a Average tumor volumes in the control and lapatinib treatment groups are presented as means
± S.E. Images of syngeneic tumors after 14 days of lapatinib treatment are shown in (b). c Syngeneic tumor-grafted control and lapatinib
(100 mg/kg/day for 14 days)-treated mice were injected with BrdU 90 min before euthanization Then tumors were excised and prepared for IHC
analysis of BrdU nuclear incorporation. BrdU-positive cells are indicated by brown staining. d TUNEL staining of apoptotic cells is indicated by
brown staining in tumor tissues from control and lapatinib-treated mice. BrdU-positive and TUNEL-positive cell percentages are graphed as the
means ± S.E. (** p < 0.01)
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exposure has a profound impact on mammary ductal
growth, which contributes to the delayed tumor onset in
lapatinib-treated mice. To understand the cellular mecha-
nisms underlying lapatinib-associated tumor inhibition
and morphogenic reprogramming, we examined the pro-
liferative status and apoptosis in mammary tissues from
24-week-old mice at the conclusion of lapatinib treatment
using BrdU incorporation and TUNEL assays, respect-
ively. As seen in Fig. 4b, lapatinib induced a striking
decrease in the number of BrdU+ cells as compared to the
control mammary gland samples, which is indicative of
decreased cell proliferation. Interestingly, TUNEL assay
data showed fewer apoptotic cells in the mammary gland
tissues from lapatinib-treated mice as compared to the
vehicle-treated mice (Fig. 4c). More apoptotic cells in the
control tissues, especially in hyperplastic regions, could be
explained by mitotic catastrophe in highly proliferative
cells, which will be addressed in the Discussion section.
Altogether, these data highlight the impact of short-term
lapatinib exposure on mammary morphogenesis and sug-
gest that lapatinib-mediated anti-proliferative effects may
not only inhibit the growth of mammary epithelial cells,
but also induce mammary reprogramming that contrib-
utes to long-term protection from mammary tumorigen-
esis even after drug withdrawal in MMTV-erbB-2 mice.
Short-term lapatinib exposure inhibits RTK and ER
signaling pathways in mammary tissues from MMTV-
erbB-2 transgenic mice
To understand the molecular signaling in mammary
tissues after short-term lapatinib treatment, we analyzed
the protein expression and phosphorylation of key
markers in the RTK and ER signaling pathways. As shown
in Fig. 5a, lapatinib treatment induced a striking decrease
in the protein levels of EGFR, p-EGFR, p-erbB-2, erbB-3,
p-Erk1/2, and p-Akt1, indicating its effective regulation of
growth factor activation and downstream PI3K/Akt and
MAPK/Erk signaling. We found that both the expression
and activation/phosphorylation of ERα were also signifi-
cantly downregulated in a pattern similar to p-Akt1 and
p-Erk1/2 downregulation. Consistently, protein levels of
common ERα targets, including Cyclin D1, c-myc, and
Bcl-2, were downregulated (Fig. 5b). In accordance with
Western blot data, lapatinib significantly depleted the per-
centage of ER+ cells in these premalignant tissues as de-
tected by IHC (Fig. 5c). To further understand the
mechanistic functions of lapatinib, we explored the effects
of lapatinib on mRNA expression of several genes in-
volved in RTK and ER signaling in premalignant tissues.
The results showed that lapatinib altered EGFR, erbB-2,
and erbB-3 mRNA levels alongside ER gene expression
(ESR1) and downstream targets Cyclin D1, c-jun, and c-
myc (Fig. 5d). To note, T/erbB-2 (erbB-2 transgene)
mRNA levels were not significantly affected by lapatinib
treatment, suggesting that lapatinib does not interfere
with MMTV-driven erbB-2 expression. Overall, these data
demonstrate that lapatinib decreases tumor latency and
mammary gland morphogenesis by negatively regulating
the EGFR/erbB-2 and ERα signaling pathways. Moreover,
concomitant alterations of EGFR/erbB-2 and ERα signal-
ing suggest that lapatinib inhibits erbB-2-ER crosstalk in
mammary tissues from MMTV-erbB-2 mice with short-
term drug exposure.
Lapatinib inhibits the stemness of erbB-2-overexpressing
breast cancer in vitro
Previous reports have demonstrated that EGFR/erbB-2 and
ER signaling can regulate mammary stem cells [31, 32]. To
explain how short-term lapatinib exposure induced long-
term protection from mammary tumor development, we
postulated that the underlying mechanism involves
lapatinib-mediated inhibition of tumor-initiating/cancer
stem cells (CSCs). To this end, we investigated the conse-
quences of lapatinib on in vitro cell lines with stem-like
properties. Using tumorsphere assays, we demonstrated that
exposure to low dose lapatinib inhibited both primary and
secondary tumorsphere formation in erbB-2-overexpressing
BT474 and 78617 cells, suggesting that lapatinib impairs the
stemness and self-renewal capacity of these cells (Fig. 6a-b).
We then investigated the effects of lapatinib on the ALDH+
cell populations in SKBR3, a classical ALDH-expressing cell
line, and the mammary tumor-derived 78617 cells. As dem-
onstrated in Fig. 6c, lapatinib significantly suppressed the
percentage of ALDH+ cells, which is indicative of the CSC
population, in both cell lines. Taken together, these results
further provide evidence of the anti-cancer properties of
lapatinib and suggest a possible mechanism of action for the
long-lasting effects that we demonstrated with short-term
exposure to lapatinib in MMTV-erbB-2 mice.
Fig. 3 Short-term lapatinib exposure during the risk window
increases mammary tumor latency in MMTV-erbB-2 transgenic mice.
Mice were treated with lapatinib (100 mg/kg/day) from weeks 16-24
(8 weeks total). Mammary tumor latencies are presented with a
Kaplan-Meier survival curve. The average latency for control and
lapatinib groups were 37 and 42 weeks, respectively (p = 0.0154)
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Discussion
erbB-2-overexpressing breast cancers comprise nearly
one-third of all breast cancer cases and are refractory to
many therapeutics as drug-resistance often arises [4].
Therefore, the development of novel preventative strat-
egies is crucial for women at a high-risk for this devas-
tating disease. In this study, we explored a novel
chemopreventative strategy using short-term, low dose
lapatinib exposure to prevent mammary tumor develop-
ment in MMTV-erbB-2 transgenic mice. We
demonstrated that short-term lapatinib exposure during
the premalignant risk window significantly delayed
mammary tumor development, which was preceded by
mammary gland growth inhibition in MMTV-erbB-2
mice. These growth inhibitory effects were associated
with suppression of the MAPK/Erk pathway, PI3K/Akt
pathway, and cell cycle progression (cyclin D1) in the
premalignant mammary tissues in vivo, and the stemness
of possible CSCs in vitro. Our results support the poten-
tial use of lapatinib as a chemopreventative agent and, in
Fig. 4 Lapatinib exposure impedes mammary morphogenesis and suppresses cell proliferation. a Mammary gland whole mounts were prepared
from 24-week-old mice of control and lapatinib (100 mg/kg/day for 8 weeks)-treated groups. Representative images are shown at 7.5x and 30x
magnification. The average number of side branches per 10 mm2 is graphed as the mean ± S.E. in the right panel (** p < 0.01). b Control and
lapatinib (100 mg/kg/day for 8 weeks)-treated mice were injected with BrdU 90 min before euthanization at 24 weeks of age and then were
prepared for IHC analysis of BrdU nuclear incorporation. BrdU-positive cells are indicated by brown staining. c TUNEL staining of apoptotic cells is
indicated by brown staining in mammary gland tissues from 24-week-old vehicle and lapatinib-treated mice. BrdU-positive and TUNEL-positive
cell percentages are graphed as the means ± S.E. (** p < 0.01)
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particular, provide proof of concept of short-term expos-
ure to erbB-2/EGFR-targeting agents to achieve long-term
protective effects.
Before in vivo testing of lapatinib-associated preventa-
tive effects, we examined the effects of lapatinib on 78617
and 85815 cells, two mammary tumor cell lines derived
from MMTV-erbB-2 transgenic mice. Consistent with
previous xenograft studies testing lapatinib-mediated
effects on human breast cancer cell lines [21–28], data
from our in vitro assays and syngeneic tumor models
demonstrated that these tumor-derived cells were highly
sensitive to lapatinib (Figs. 1 and 2). The doses used in our
experiments were well-tolerated, which provides funda-
mental guidance for selecting the dose for our prevention
study (Fig. 3). As a dual inhibitor of erbB-2 and EGFR,
lapatinib also induced potent inhibition of the phosphoryl-
ation/activation of both RTKs, which led to remarkable
suppression of PI3K/Akt and MAPK/Erk pathways, and
other critical downstream regulators (Fig. 1). These sensi-
tive biochemical and phenotypic changes not only demon-
strate the therapeutic efficacy of lapatinib, but also
support its potential as a chemopreventative agent.
Fig. 5 Lapatinib inhibits RTK and ER signaling pathways in vivo. a, b Total and phosphorylated protein levels of indicated markers in the mammary
tissues (at 24 weeks of age) of mice from control and lapatinib (100 mg/kg/day for 8 weeks)-treated groups were detected using Western blotting.
Protein samples from 3 mice in each group are shown. c Mammary tissue sections were prepared from 24-week-old control mice and mice treated
with lapatinib (100 mg/kg/day) for 8 weeks. Percentages of ERα-positive cells were graphed as the means ± S.E. (* p < 0.05). Representative images of
IHC analysis are shown with brown staining indicating ERα-positive cells. d mRNA levels of indicated markers in the mammary tissues of 24-week-old
mice from control and lapatinib groups were quantified using real-time PCR. The relative mRNA expression of each indicated gene was graphed as
means ± S.E. (* p < 0.05 versus the control for each gene)
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Recently, small molecule inhibitors targeting RTKs have
been investigated for their potential chemopreventative
effects. Using the MMTV-erbB-2 mouse model, it has been
shown that treatments with EGFR-targeting gefitinib or
lapatinib both significantly inhibited the formation of
premalignant lesions in the mammary glands and delayed
spontaneous tumor development [19, 33]. In a recent
clinical trial by DeCensi et al. (2011), lapatinib was adminis-
tered to 60 women with erbB-2/Her2+ ductal carcinoma in
situ (DCIS) for 3 weeks between the diagnostic biopsy and
surgery [34]. Their results showed that this short-term lapa-
tinib treatment decreased cell proliferation in ductal intrae-
pithelial neoplasia (DIN), ductal hyperplasia without atypia
(DH), and invasive erbB-2/Her2+ breast cancer. Data from
both preclinical models and clinical trials support lapatinib
as a preventative agent for women at risk for erbB-2/Her2+
breast cancers. While these advances provide the rationale
for further clinical development exploiting the preventative
capacity of lapatinib, more studies are needed to define opti-
mal exposure timing treatment conditions.
Previously it was reported that treating MMTV-erbB-2
transgenic mice with 75 mg/kg BW lapatinib twice a day
from 3 to 15 months of age resulted in inhibition of
premalignant lesions and mammary tumor development
[19]. In contrast to life-long (approximately 52 weeks)
lapatinib exposure in MMTV-erbB-2 mice from the
above study, we adopted the 8 week lapatinib treatment
schedule to determine the preventative efficacy of a sin-
gle daily dose of lapatinib (100 mg/kg/day) given for a
short period of time during the risk window prior to
tumor development. We demonstrated that this treat-
ment regimen significantly delayed mammary tumor de-
velopment by 5 weeks in MMTV-erbB-2 transgenic
mice (Fig. 3). Specifically, the average tumor latency in-
creased from 37 weeks in the vehicle-treated mice to
42 weeks in the lapatinib-treated mice after only a short
treatment. Consistent with our hypothesis, short-term
lapatinib exposure prior to tumor development induced
long-lasting cancer preventative effects. Although the
tumor inhibition observed in our study was not as
Fig. 6 Lapatinib inhibits the stemness of erbB-2-overexpressing breast cancer in vitro. BT474 (a) and 78617 (b) cells were cultured in vitro and
subjected to primary and secondary tumorsphere assays. In the primary tumorsphere assay, cells were initially treated with lapatinib (0, 0.1, or
0.3 μM) for 6 days for primary sphere formation. Then primary tumorspheres were harvested and replated for another 6 days under identical
incubation conditions to form secondary spheres. Primary and secondary tumorsphere formations were recorded. Values are presented as the
means ± S.E. (** p < 0.01 as compared to the corresponding untreated control samples). Representative images from each assay are depicted in
the right panels. c SKBR3 and 78617 cells were treated with lapatinib (0, 1, or 3 μM) for 40 h, followed by quantification of ALDH-positive cells.
The percentage of ALDH-positive cells was determined using the ALDEFLUOR detection kit with flow cytometry. Values are presented as the
means ± S.E. (* p < 0.05; ** p < 0.01 as compared to the control for each cell line)
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impressive as the previous report by Strecker et al. [19]
using long-term lapatinib treatment, the considerably
shorter lapatinib treatment used in our study produced a
substantial protective benefit. With further optimization
of lapatinib doses and/or possible combination with
other preventative agents, the outcomes of short-term
lapatinib exposure could be greatly improved.
The significant lapatinib-induced changes in tumor la-
tency that we demonstrate in Fig. 3 were also associated
with substantial inhibition of epithelial cell proliferation
and premalignant lesions (Fig. 4). In this regard, our
morphogenic data showed that short-term lapatinib
treatment resulted in striking changes in histopatho-
logical patterns and proliferative status, as indicated by
decreases in ductal growth, lateral branching, epithelial
density, and BrdU incorporation in mammary tissues
from MMTV-erbB-2 mice (Fig. 4). These changes are
consistent with the inhibition of erbB-2/EGFR signaling,
which has a broad impact on ductal growth and mor-
phogenesis in glandular and tumor development. Like-
wise, the alterations might be part of lapatinib-induced
reprogramming that confers long-term protection from
tumor development in this model. In the examination of
apoptosis in the lapatinib-treated mammary gland
tissues, we reported fewer TUNEL+ cells than in the
control samples. This observation can be explained by
highly proliferative cells in the tissues from vehicle-
treated mice, which are associated with more apoptotic
cell death through mitotic catastrophe and remarkable
decreases in proliferative cells from lapatinib-treated
mice [35, 36]. Although we did not see lapatinib-
induced apoptosis at the given endpoint, we cannot rule
out apoptosis induction during the initial, acute phase of
lapatinib treatment. Our Western blot and PCR data in-
dicated that short-term lapatinib exposure induces
marked inhibition of erbB-2/EGFR signaling and down-
stream pathways/targets, which corroborates our in vitro
results (Fig. 5). While these data confirm the connection
between RTK inhibition and ultimate tumor prevention,
the results also suggest that lapatinib may induce a
broader impact on erbB-2/EGFR signaling beyond the
canonical regulatory pathways. For instance, concurrent
inhibition of erbB-2 and ER in mammary tissues
suggests that lapatinib may block the crosstalk between
these two signaling molecules, leading to downstream
effects on multiple pathways. Together, our data indicate
that the effects on morphogenesis and molecular signal-
ing pathways are involved in the underlying mechanisms
of short-term lapatinib exposure associated with
mammary tumor prevention.
Recent progress in stem cell research indicates that
mammary stem cells contribute to tumor heterogeneity,
initiation, recurrence, and invasive potential through
the differentiation into CSCs [37–40]. Due to the
implication of CSCs in mammary tumor development
and metastasis, stem cell-targeting therapies have been
developed and are a proven therapeutic strategy [41–
44]. In particular, numerous reports have shown that
metformin selectively inhibits CSCs in erbB-2+ breast
cancer models [42–44]. To this end, we examined
stemness in erbB-2-overexpressing tumor-derived cells
and cell lines (Fig. 6). Our findings indicated that lapa-
tinib inhibits tumorsphere stemness and self-renewal,
which is represented by decreased primary and second-
ary tumorsphere numbers after lapatinib treatment.
ALDH1 activity/overexpression is correlated to CSCs
and poor prognosis in various tissue-specific cell types,
including mammary epithelial cells [45–47]. As such,
we demonstrated that lapatinib suppressed ALDH1 ac-
tivity in 78617 mammary tumor-derived cells and
BT474 breast cancer cells. Overall, our data indicate
that lapatinib inhibits CSC-like properties in vitro, pro-
viding a plausible mechanism for the anti-tumorigenic
effects that we report in vivo.
Conclusions
In conclusion, short-term exposure to lapatinib during
the premalignant risk window for developing erbB-2-
overexpressing mammary tumors resulted in a striking
shift in tumor onset, which was preceded by delayed
mammary morphogenesis and inhibition of molecular
signaling pathways that regulate cell proliferation, cell
survival, and stem cell self-renewal. Our study suggests
that short-term, low dose lapatinib exposure during the
premalignant phase of breast cancer development is a
promising strategy to prevent the development of erbB-
2-overexpressing mammary tumors. A short-term, low
dose chemoprevention protocol not only improves
patient compliance, but also minimizes chronic side
effects, making short-term lapatinib exposure a poten-
tially ideal preventative strategy with long-lasting
outcomes.
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